Abstract
Childhood dystonia that does not respond to treatment with levodopa (dopa-nonresponsive dystonia, DND) has an unclear pathogenesis and is notoriously difficult to treat. To test the hypothesis that there may be abnormalities in serotonin turnover in DND we measured cerebrospinal fluid (CSF) concentrations of homovanillic (HVA) and 5-hydroxyindoleacetic (HIAA) acids, metabolites of dopamine and serotonin, respectively, in 18 children with dystonia not responsive to levodopa. These were combined with a reference population of 85 children with neurologic or metabolic disease known not to affect dopamine or serotonin metabolism. Because of the known natural age-related decrement in HVA and HIAA concentrations, the results were analyzed using multiple regression using age and DND as predictors of CSF HIAA and HVA concentrations. DND was a highly significant predictor of CSF HIAA concentration (p < 0.001) but not of CSF HVA concentration (p = 0.59). After fitting a regression model, the geometric mean ratio of CSF HIAA in DND compared with the reference range was 0.53 whereas that for CSF HVA was 0.95. We also analyzed CSF HIAA/HVA ratios. After fitting a regression model, we found no dependence on age, and the mean of CSF HIAA/HVA in DND was 0.28 whereas that for the reference range was 0.49 (p < 0.001). We conclude that a significant number of children with DND have reduced CNS serotonin turnover. Treatment with drugs that increase serotonin concentration in the synaptic cleft should be considered in this group of patients.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
Abbreviations
- CSF:
-
cerebrospinal fluid
- HIAA:
-
5-hydroxyindoleacetic acid
- HVA:
-
homovanillic acid
- DND:
-
dopa-nonresponsive dystonia
References
Surtees R, Clayton P 1998 Infantile parkinsonism-dystonia: tyrosine hydroxylase deficiency. Mov Disord 13: 350
Bandmann O, Valente EM, Holmans P, Surtees RA, Walters JH, Wevers RA, Marsden CD, Wood NW 1998 Dopa-responsive dystonia: a clinical molecular genetic study. Ann Neurol 44: 649–656
Hyland K, Surtees RA, Rodeck C, Clayton PT 1992 Aromaticl-amino acid decarboxylase deficiency: clinical features, diagnosis, treatment of a new inborn error of neurotransmitter amine synthesis. Neurology 42: 1980–1988
Hyland K 1993 Abnormalities of biogenic amine metabolism. J Inherit Metab Dis 16: 676–690
Ludecke B, Knappskog PM, Clayton PT, Surtees RA, Clelland JD, Heales SJ, Brand MP, Bartholome K, Flatmark T 1996 Recessively inheritedl-DOPA-responsive parkinsonism in infancy caused by a point mutation (L205P) in the tyrosine hydroxylase gene. Hum Mol Genet 5: 1023–1028
Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ 1986 Interacting neurotransmitter systems: a non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatr Res 20: 175–193
Hyland K, Surtees RA, Heales SJ, Bowron A, Howells DW, Smith I 1993 Cerebrospinal fluid concentrations of pterins metabolites of serotonin dopamine in a pediatric reference population. Pediatr Res 34: 10–14
Nobin A, Bjorklund A 1973 Topography of the monoamine neuron systems in the human brain as revealed in fetuses. Acta Physiol Scand Suppl 388: 1–40
Azmitia EC 1978 The serotonin-producing neurons of the midbrain median dorsal raphe nuclei. Handb Psychopharmacol 9: 233–314
Steinbusch HWM 1981 Distribution of serotonin-immunoreactivity in the central nervous system of the rat: cell bodies terminals. Neuroscience 6: 557–618
Azmitia EC, Gannon PJ 1986 The primate serotonergic system: a review of human animal studies a report on Macaca fascicularis. Adv Neurol 43: 407–468
Molliver ME 1987 Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol 7: 3S–23S
Naumann M, Gotz M, Reiners K, Lange KW, Riederer P 1996 Neurotransmitters in CSF of idiopathic adult-onset dystonia: reduced 5-HIAA levels as evidence of impaired serotonergic metabolism. J Neural Transm 103: 1083–1091
Plaznik A, Jessa M, Nazar M 1997 The behavioral effects of NMDA antagonists in serotonin depleted rats. Pharmacol Biochem Behav 58: 159–166
Wieland S, Lucki I 1991 Altered behavioral responses mediated by serotonin receptors in the genetically dystonic (dt) rat. Brain Res Bull 26: 11–16
Loscher W, Richter A 1994 The novel selective silent 5-HT1A receptor antagonist (+)-WAY-100135 aggravates dystonic movements in a mutant hamster model. Eur J Pharmacol 255: 235–238
Mathew NT, Tietjen GE, Lucker C 1996 Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia 16: 323–327
Leo RJ 1996 Movement disorders associated with the serotonin selective reuptake inhibitors. J Clin Psychiatry 57: 449–454
Gerber PE, Lynd LD 1998 Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 32: 692–698
Moir AT, Ashcroft GW, Crawford TB, Eccleston D, Guldberg HC 1970 Cerebral metabolites in cerebrospinal fluid as a biochemical approach to the brain. Brain 93: 357–368
Young SN, Garelis E, Lal S, Martin JB, Molina Negro P, Ethier R, Sourkes TL 1974 Tryptophan 5-hydroxyindoleacetic acid in human cerebrospinal fluid. J Neurochem 22: 777–779
Garelis E, Sourkes TL 1973 Sites of origin in the central nervous system of monoamine metabolites measured in human cerebrospinal fluid. J Neurol Neurosurg Psychiatry 36: 625–629
Garelis E, Young SN, Lal S, Sourkes TL 1974 Monoamine metabolites in lumbar CSF: the question of their origin in relation to clinical studies. Brain Res 79: 1–8
Sourkes TL, Young SN, Garelis E, Lal S 1975 Gradients of concentrations of tryptophan 5- hydroxyindoleacetic acid (5-HIAA) in cerebrospinal fluid (CSF). Acta Vitaminol Enzymol 29: 97–99
Brauetigam C, Wevers RA, Jansen RJ, Smeitink JA, de-Rijk-van-Andel JF, Gabreels FJ, Hoffmann GF 1998 Biochemical hallmarks of tyrosine hydroxylase deficiency. Clin Chem 4: 1897–1904
Lowe J, Lennox G, Leigh PN 1997 Disorders of movement and system degenerations. In: Graham DI, Lantos PL (eds) Greenfield's Neuropathology. Arnold, London, 281–366
Tork I 1990 Anatomy of the serotonergic system. Ann N Y Acad Sci 600: 9–34
Author information
Authors and Affiliations
Corresponding author
Additional information
Supported by a grant from the Deutsche Forschungsgemeinschaft (B.A.).Current address (M.K.): Fachklinik Hohenstücken, Brahmsstrasse 38, D-14772 Brandenburg, Germany.
Rights and permissions
About this article
Cite this article
Assmann, B., Köhler, M., Hoffmann, G. et al. Selective Decrease in Central Nervous System Serotonin Turnover in Children with Dopa-Nonresponsive Dystonia. Pediatr Res 52, 91–94 (2002). https://doi.org/10.1203/00006450-200207000-00017
Received:
Accepted:
Issue date:
DOI: https://doi.org/10.1203/00006450-200207000-00017
This article is cited by
-
Lower serotonin transporter binding in patients with cervical dystonia is associated with psychiatric symptoms
EJNMMI Research (2017)
-
Monoamine neurotransmitter disorders—clinical advances and future perspectives
Nature Reviews Neurology (2015)
-
Genome-wide association study of monoamine metabolite levels in human cerebrospinal fluid
Molecular Psychiatry (2014)
-
Cerebrospinal fluid alterations of the serotonin product, 5‐hydroxyindolacetic acid, in neurological disorders
Journal of Inherited Metabolic Disease (2010)
